New opportunities in Haemophilia treatment: Efmoroctocog Alfa for patients with Haemophilia A
Recently new opportunities are emerging for improving the way patients with Haemophilia A are treated. Among these opportunities, efmoroctocog alfa is a first-in-class recombinant factor VIII-Fc fusion protein (rFVIIIFc) produced by recombinant DNA technology with an extended half-life compared w...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Milano University Press
2022-01-01
|
| Series: | Epidemiology, Biostatistics and Public Health |
| Online Access: | https://riviste.unimi.it/index.php/ebph/article/view/17195 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|